At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Roflumilast +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults
In Brief
A Phase 1 clinical trial evaluating Roflumilast, Roflumilast placebo, and 3 other interventions for Memory Impairment and Alzheimer's Disease. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMemory Impairment, Alzheimer's Disease
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedJan 2014
Primary CompletionMay 2014
TodayJul 2026
First PostedJan 31, 2014
Enrollment StartJan 1, 2014
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.4 years ago
Interventions
Roflumilastdrug
Roflumilast tablets
Roflumilast placebodrug
Roflumilast placebo-matching tablets
Donepezildrug
Donepezil overencapsulated tablets
Donepezil placebodrug
Donepezil placebo-matching overencapsulated tablets
Scopolaminedrug
Scopolamine subcutaneous injection